Second-line indication for ENHERTU
Join our broadcast to hear experts discuss more about the new second-line indication for ENHERTU®. Now approved to treat certain patients with HER2+ Metastatic Breast Cancer
Available Sessions June 16, 2022 6:30PM ET June 16, 2022 8:00PM ET June 16, 2022 9:30PM ET Registration: https://studio.mjhassoc.com/reach/2L-HER2Pos-mBC |
|